KLS-3021 / Kolon Life Sci - LARVOL DELTA

Demonstrating efficacy of KLS-3021, oncolytic vaccinia virus, on PC-3 human prostate cancer cells growing in prostate and regional lymph nodes using orthotopic mouse models (ESMO 2025) - "Mice were treated with vehicle, docetaxel (10 mg/kg, i.v., weekly), or KLS-3021 (1×10 7 TCID 50 , lobular or intratumoral, single dose). Legal entity responsible for the study Kolon Life Science, Inc. Funding Kolon Life Science, Inc."

Oncolytic virus • Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • IL12A • SPAM1

Kolon Life Science unveiled preclinical data for KLS-3021 via an e-poster at the European Society for Medical Oncology Annual Congress (ESMO 2025)… (Korea Biomedical Review) - "In preclinical studies using a syngeneic mouse model with prostate cancer cells (PC3), the KLS-3021 monotherapy group showed a significant reduction in tumor volume compared to the chemotherapy drug docetaxel (10 mg/kg, intravenously once weekly). Notably, tumor clearance was confirmed in both the primary lesion and lymph nodes even in a locally invasive model where lymph node metastasis was observed."

Preclinical • Prostate Cancer

Kolon Life Science presents 'KLS-3021' as a treatment for squamous cell carcinoma of the skin at ASGCT [Google translation] (BioTimes) - "Kolon Life Science announced on the 19th that it had presented a poster presentation on the preclinical results of its anticancer treatment candidate 'KLS-3021' for cutaneous squamous cell carcinoma (cSCC) at the '2025 American Society for Gene and Cell Therapy (ASGCT)' held in New Orleans, USA from the 13th to the 17th (local time)....The research team observed that the tumor completely disappeared with just a single injection of KLS-3021 into the tumor in an orthotopic tumor model1 anticancer efficacy evaluation. In particular, in the metastatic tumor model, the therapeutic effect was shown to extend to adjacent lymph nodes as well as the primary tumor, suggesting the possibility of future metastatic cancer treatment."

Preclinical • Squamous Cell Skin Cancer

KLS-3021: Innovative Oncolytic Virotherapy for the Treatment of Advanced and Metastatic Cutaneous Squamous Cell Carcinoma (ASGCT 2025) - "Preclinical evaluation of KLS-3021 demonstrates its potential as a potent oncolytic virotherapy for advanced and metastatic cSCC. KLS-3021 showed selective cytotoxicity and robust replication in cSCC cell lines, leading to significant tumor regression and effective eradication of metastatic lesions. The observed hyaluronan degradation, enhanced viral dissemination, and favorable immune cell infiltration highlight its multifaceted mechanism."

IO biomarker • Late-breaking abstract • Metastases • Oncolytic virus • Genetic Disorders • Infectious Disease • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • IL12A • SPAM1

Kolon Life Science secures European patent for oncolytic virus therapy KLS-3021 (Korea Biomedical Review) - "Kolon Life Science announced Thursday that Europe has granted a patent titled 'recombinant vaccinia virus and pharmaceutical composition comprising same,' related to KLS-3021, a gene therapy candidate for the treatment of solid tumors. This European patent marks the ninth registration, following approvals in Korea, Japan, Canada, Singapore, and China. The patent is currently under review in the U.S. and Brazil."

Patent • Oncology • Solid Tumor